BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...
Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million ...
It will compare the shot against a licensed inactivated vaccine ... annually. BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting ...
HealthDay on MSN47m
New vaccine shows promise for patients with aggressive breast cancerAn experimental vaccine could offer fresh hope to women diagnosed with an aggressive and hard-to-treat form of breast cancer, ...
A small clinical trial shows promising results for patients with triple-negative breast cancer who received an ...
News Medical on MSN7h
New vaccine shows potential in preventing recurrence of triple-negative breast cancerA small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.
KMOX News Radio St. Louis on MSN4h
Wash U researchers find vaccine that shows promise against aggressive breast cancerWashington University researchers find a vaccine that shows promise against aggressive breast cancer. KMOX Health Editor Fred ...
University of Zagreb researcher Beata Halassy treated her breast cancer with an unproven virus-based therapy using viruses ...
Breast cancer patients have been given fresh hope after a new vaccine showed "promise" in treating an aggressive form of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback